3P Biopharmaceuticals presents its growth plan at BIOSPAIN to further expand its operations in Europe and the USA

3P Biopharmaceuticals, a leading CDMO (contract development and manufacturing organisation) specialising in process development and cGMP (good manufacturing practice) manufacturing of biologics and cell therapy products, presents its growth plan at BIOSPAIN.

By 2025, 3P plans to invest 40 million Euro to consolidate its position in the global market for new biological drug development and manufacturing. The investment plan, which the CDMO is carrying out over a 5 year period; 15 million has already been invested during the last 2 years and a further 25 million will be invested by end of 2025 is aimed at increasing capacity and incorporating additional state-of-the-art development and manufacturing technologies. “At 3P we remain committed to growth. The entry of Keensight Capital in 2019, one of Europe’s leading private equity managers specialising in healthcare, as a majority shareholder, is allowing us to focus on capacity expansion and technological adaptation, as well as greater internationalisation. Our goal is to expand further in Europe and thus prepare for a greater presence in the US market,” explains Dámaso Molero, CEO of 3P Biopharmaceuticals.

The investments

In the field of mammalian cell-based protein production, 3P will bring an expanded production suite on-line at the end of October, which will increase its capacity to manufacture these proteins ten-fold, reaching a scale of 2,000l per batch with single-use technology (disposable bioreactors). A second 2000l single-use bioreactor will be brought on-line in 2022. In parallel, it will increase by 50% its capacity to manufacture proteins from bacteria and yeasts, with a third upstream line to be launched before the end of 2021 and a third downstream purification line planned for 2022.

After expansion, the company’s facilities will reach a total of 9000m² across three buildings, where offices, process development, production and analytical areas will be distributed including1000m² of space entirely dedicated to laboratories for the development of analytical methods and quality control.

30% annual growth

In 2020 3P Biopharmaceuticals closed the year with a turnover of 33 million Euro and an ebidta operating profit of more than 9 million Euro. Nearing its 15th anniversary and with an annual growth of 30% since its inception, 3P Biopharmaceuticals has doubled its number of employees since 2017. “We now employ more than 300 people and are currently working together with 19 clients consolidating ongoing projects and starting new ones. Every development we carry out is aimed to cure, or at least improve, the quality of life of thousands of people,” explains the CEO.

3P is currently working on several projects for different indications and is also collaborating with a French company on the development of a vaccine against Covid-19 and with a Swedish company, looking at a treatment for the disease. In addition, 3P regularly manufactures the first biosimilar developed in Spain for treating people who have received chemotherapy for cancer; the only vaccine in the world against Leishmania in dogs; and is about to manufacture another vaccine against mumps in horses, which has just been approved by the EMA.

3P is a key driving force, not only for the region of Navarra, but also at national level, the reason why it is a member of the board of directors of Spanish Biotechnology Association (Asebio) and a silver sponsor of BIOSPAIN. It has an important presence during the fair, participating in 3 round table discussions: one on attracting talent, another in which future global pandemic scenarios and possible solutions for an effective response will be debated, and finally, “New challenges in the development and manufacture of monoclonal antibodies”, an area in which the company is making a clear commitment to the future.

View the full press release here